Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy

Blood Adv. 2022 Aug 23;6(16):4719-4725. doi: 10.1182/bloodadvances.2022007776.

Kai Rejeski^{1

2

3}, Andreas Burchert⁴, Gloria Iacoboni^{5

6}, Pierre Sesques⁷, Lars Fransecky⁸, Veit Bücklein^{1

2}, Corinna Trenker⁴, Rafael Hernani⁹, Ralph Naumann¹⁰, Jonas Schäfer⁴, Viktoria Blumenberg^{1

2

3}, Christian Schmidt¹, Kristina Sohlbach⁴, Michael von Bergwelt-Baildon^{1

3}, Emmanuel Bachy⁷, Pere Barba^{5

6}, Marion Subklewe^{1

2

3}

¹ Department of Medicine III, Hematology and Oncology, University Hospital, LMU Munich, Munich, Germany.
² Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany.
³ German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany.
⁴ Department of Internal Medicine, Hematology, Oncology and Immunology, Philipps University Marburg and University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany.
⁵ Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall d'Hebron, Barcelona, Spain.
⁶ Department of Medicine, Universitat Autònoma of Barcelona (UAB), Bellaterra, Spain.
⁷ Hospices Civils de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, Pierre-Bénite, France.
⁸ Medical Department II-Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany.
⁹ Department of Hematology, Hospital Clínico Universitario, Institute for Research INCLIVA, Valencia, Spain; and.
¹⁰ Medical Department III-Hematology and Oncology, St. Marien-Krankenhaus Siegen, Siegen, Germany.

No abstract available

Publication types